Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB001 in Metastatic Castration Resistant Prostate Cancer
NCT07214961Phase 1Active, not recruiting
- Sponsor
- ARTBIO
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Peptides, Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AB001 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by ARTBIO. Primary endpoints: Safety and tolerability profile of AB001, Recommended AB001 Dose and 3 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
AB001
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07214961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214961.